Royal Bank Of Canada Passage Bio, Inc. Transaction History

Royal Bank Of Canada

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.79 - $1.58 $152 - $304	193 Added 38.6%	693 $0
Q1 2024 Nov 05, 2024	SELL	$0.86 - $1.73 $165 - $333	-193 Reduced 27.85%	500 $0
Q1 2024 May 15, 2024	BUY	$0.86 - $1.73 $104 - $209	121 Added 31.93%	500 $0
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.01 $203 - $342	339 Added 847.5%	379 $0
Q3 2023 Nov 14, 2023	SELL	$0.66 - $1.01 $407 - $624	-618 Reduced 93.92%	40 $0
Q2 2023 Aug 14, 2023	BUY	$0.82 - $1.19 $439 - $637	536 Added 439.34%	658 $0
Q4 2022 Feb 14, 2023	SELL	$1.06 - $1.48 $24 - $34	-23 Reduced 15.86%	122 $0
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $581 - $1,182	-477 Reduced 76.69%	145 $0
Q2 2022 Aug 15, 2022	SELL	$1.63 - $3.46 $2,899 - $6,155	-1,779 Reduced 74.09%	622 $1,000
Q1 2022 May 16, 2022	SELL	$2.66 - $6.49 $14,105 - $34,416	-5,303 Reduced 68.83%	2,401 $7,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $16,848 - $27,539	2,700 Added 53.96%	7,704 $48,000
Q3 2021 Nov 15, 2021	BUY	$9.73 - $15.52 $13,086 - $20,874	1,345 Added 36.76%	5,004 $50,000
Q2 2021 Aug 16, 2021	BUY	$12.44 - $19.45 $45,517 - $71,167	3,659 New	3,659 $49,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.